0

Venlafaxine for Depression in Head and Neck Cancer Patients

JG
Overseen ByJessica Grayson, MD
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: University of Alabama at Birmingham
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this research study is to initiate a pharmacotherapy protocol for at-risk patients with newly diagnosed head and neck cancer in order to decrease the incidence of anxiety, depression, and uncontrolled pain during cancer treatment.

Who Is on the Research Team?

JG

Jessica Grayson, MD

Principal Investigator

University of Alabama at Birmingham

Are You a Good Fit for This Trial?

This trial is for adults over 18 with newly diagnosed head and neck cancer who are about to start treatment. They must be able to take oral medication, speak English, and commit to the study's duration. Pregnant or nursing women, those on current depression/anxiety meds, with certain thyroid cancers or severe mental health conditions can't join.

Inclusion Criteria

Stated willingness to comply with all study procedures and availability for the duration of the study
Willing to adhere to the study drug's dosing protocol
Provision of signed and dated informed consent form
See 4 more

Exclusion Criteria

I have been diagnosed with psychosis, schizophrenia, or severe depression.
I have chronic pain that is not well-managed.
I am pregnant or nursing.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants in the treatment group receive venlafaxine with dose titration over 3 weeks, while the control group receives no pharmacological treatment

3 weeks
3 visits (telephone)

Initial Follow-up

Participants follow up 6-8 weeks after beginning their chosen treatment regimen for head and neck cancer, completing study questionnaires and vital sign collection

6-8 weeks
1 visit (in-person)

Extended Follow-up

Participants are monitored every three months for up to one year, with vital signs, concomitant medications, adverse events, and questionnaire responses collected

9 months
3 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Venlafaxine
Trial Overview The trial is testing Venlafaxine as a way to reduce anxiety, depression, and pain in patients undergoing treatment for head and neck cancer. It aims to establish a protocol for early pharmacotherapy in these patients.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment GroupExperimental Treatment1 Intervention
Group II: Control GroupActive Control1 Intervention

Venlafaxine is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Efexor for:
🇺🇸
Approved in United States as Effexor for:
🇨🇦
Approved in Canada as Effexor for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security